A French medtech company founded in 2016, REGENLIFE specialises in the development of non-invasive devices for the treatment of neurological disorders. Its first medical device is currently undergoing the CE marking process for the treatment of concussion and is being studied in a Phase III trial for Alzheimer’s disease.
Read the full article on REGEnLIFE, at the intersection of medicine and physics, in Pharmaceutiques magazine, issue 335 / March 2026
Source link
